부산대학교 도서관

Its FDA approval provides a crucial option for patients who have exhausted standard therapies. B Dear Editor, b The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma.[1] Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a significant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. 148 individuals with DLBCL, not otherwise specified (NOS), including DLBCL resulting from indolent lymphoma, and high-grade B-cell lymphoma following two or more lines of systemic therapy, including at least one therapy using an anti-CD20 monoclonal antibody, make up the efficacy population. [Extracted from the article]